Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on June 17, 2016, reporting events that occurred on June 16, 2016. The filing addresses corporate governance changes, specifically the amendment of an executive employment agreement and the resignation of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms and personnel changes rather than financial performance.
Material Changes
- Executive Compensation Amendment: The Company amended the employment agreement of Michael Becker, Chief Financial Officer. The amendment establishes that if Mr. Becker is terminated other than for cause, he is entitled to severance equal to six months of base salary and health benefits.
- Executive Resignation: Elizabeth Nolan, the Company's Chief Business Officer, resigned effective June 16, 2016.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The primary focus is on the specific terms of the amended employment contract for the CFO, which includes:
- Base Salary: $232,000 annually.
- Bonus: Target of 25% of base salary based on individual and corporate objectives.
- Equity: Initial grant of 30,000 stock options (exercise price $15.25) and 20,000 restricted shares, vesting over four years.
- Non-Solicitation: A 24-month restriction on soliciting employees or clients following termination.
Investor Verification Checklist
- Verify the impact of the Chief Business Officer's resignation on ongoing business development activities.
- Review the full text of the Amendment to the Offer Letter (Exhibit 10.1) for complete legal terms regarding severance and non-solicitation.
- Confirm the status of the Company's cash reserves to ensure it can meet the potential severance obligation of six months' salary for the CFO if triggered.
- Check subsequent filings for the appointment of a replacement for the Chief Business Officer.